secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001104659-25-068362
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics amends rescission agreement adding accredited investor reps from ImmunogenX shareholders
--------------------------------------------------------------------------------

- Amendment adds Section 5(f) to Rescission Agreement, requiring each shareholder to be an accredited investor under Rule 501 of Regulation D.
- Shareholders also represent they have no need for liquidity, have evaluated investment risks, and are acquiring Membership Units for own account.
- Amendment effective July 15, 2025; parties include Entero Therapeutics, ImmunogenX LLC, and former ImmunogenX shareholders.
- Original Rescission Agreement, disclosed March 25, 2025, unwound the merger between Entero and ImmunogenX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465925068362/0001104659-25-068362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465925068362/tm2521048d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-068362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer